A Single Ascending Dose of HRS-2162 in Healthy Subjects

NCT07195604 ↗

Phase 1 Recruiting 64 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD

Timeline

Start: 2025-09-25
Primary completion: 2025-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-2162	Unknown	—	—

Indications

No indication recorded.